BAJAJ BROKING

Notification
No new Notification messages
Vishal Mega Mart IPO is Open!
Apply for the Vishal Mega Mart IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
dr. reddy s laboratories stock

DR. REDDY S LABORATORIES Share Price

1245.4 6.84 (0.55%)
Dec 12 2024 03:30 PM Pharmaceuticals NSE: DRREDDY

DR. REDDY S LABORATORIES Share Price Update

As of the latest trading session, DR. REDDY S LABORATORIES share price is currently at 1245.4, which is up by 6.84 from its previous closing. Today, the stock has fluctuated between 1226.35 and 1250.20. Over the past year, DR. REDDY S LABORATORIES has achieved a return of 13.14 %. In the last month alone, the return has been -3.83 %. Read More...

DR. REDDY S LABORATORIES Performance

Day Range

Low1226.35 High1250.20
1245.40

52 Week Range

Low 1074.00 High 1421.49
1245.40

DR. REDDY S LABORATORIES Share Price

881

500124

DRREDDY

img img img img
No Data Available

Open Price

1244.80

Prev. Close

1238.55

Volume (Shares)

1648944.00

Total traded value

20535.94

Upper Circuit

1362.40

Lower Circuit

1114.70

Note: The current prices & values are delayed, Login to your account for live updates.

DR. REDDY S LABORATORIES Fundamentals


(Standalone)

Market Cap (Cr) 20775.55
PE Ratio (TTM) 21.62
Book Value / Share 322.47
Beta 0.45
ROE 19.42%
EPS (TTM) 57.64
Dividend Yield 0.64%
Net Profit Qtr (Cr) 1882.10

DR. REDDY S LABORATORIES Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 6678.80
Operating Expense 4263.09
Net Profit 1882.10
Net Profit Margin (%) 28.18
Earnings Per Share (EPS) 113.00
EBITDA 2929.20
Effective Tax Rate (%) 28.72
Particulars JUN 2024 (Values in Cr)
Revenue 5823.90
Operating Expense 4145.10
Net Profit 1417.20
Net Profit Margin (%) 24.33
Earnings Per Share (EPS) 85.10
EBITDA 2170.80
Effective Tax Rate (%) 25.95
Particulars MAR 2024 (Values in Cr)
Revenue 5081.80
Operating Expense 3978.30
Net Profit 1034.80
Net Profit Margin (%) 20.36
Earnings Per Share (EPS) 62.14
EBITDA 1591.30
Effective Tax Rate (%) 22.72
Particulars DEC 2023 (Values in Cr)
Revenue 4083.10
Operating Expense 3698.70
Net Profit 475.20
Net Profit Margin (%) 11.63
Earnings Per Share (EPS) 28.55
EBITDA 883.90
Effective Tax Rate (%) 24.79
Particulars SEP 2023 (Values in Cr)
Revenue 4819.10
Operating Expense 3461.20
Net Profit 1192.60
Net Profit Margin (%) 24.74
Earnings Per Share (EPS) 71.68
EBITDA 1852.19
Effective Tax Rate (%) 25.49
Particulars MAR 2024 (Values in Cr)
Revenue 19404.10
Operating Expense 14554.80
Net Profit 4342.00
Net Profit Margin (%) 22.37
Earnings Per Share (EPS) 260.95
EBITDA 6788.70
Effective Tax Rate (%) 25.02
Particulars MAR 2023 (Values in Cr)
Revenue 16899.10
Operating Expense 13687.80
Net Profit 2612.80
Net Profit Margin (%) 15.46
Earnings Per Share (EPS) 157.37
EBITDA 4806.10
Effective Tax Rate (%) 32.41
Particulars MAR 2022 (Values in Cr)
Revenue 14315.30
Operating Expense 12663.40
Net Profit 1623.20
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 97.85
EBITDA 3076.10
Effective Tax Rate (%) 27.00
Particulars MAR 2021 (Values in Cr)
Revenue 13281.40
Operating Expense 11094.00
Net Profit 2186.40
Net Profit Margin (%) 16.46
Earnings Per Share (EPS) 131.84
EBITDA 3937.89
Effective Tax Rate (%) 28.46
Particulars MAR 2020 (Values in Cr)
Revenue 11803.00
Operating Expense 9817.80
Net Profit 2937.70
Net Profit Margin (%) 24.88
Earnings Per Share (EPS) 177.23
EBITDA 3612.80
Effective Tax Rate (%) -5.83
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1699.87
ROE % 21.64
ROCE % 26.59
Total Debt to Total Equity 0.06
EBITDA Margin 31.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1405.34
ROE % 21.21
ROCE % 25.99
Total Debt to Total Equity 0.11
EBITDA Margin 30.16
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1164.21
ROE % 11.84
ROCE % 14.46
Total Debt to Total Equity 0.17
EBITDA Margin 20.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1072.02
ROE % 11.74
ROCE % 15.29
Total Debt to Total Equity 0.16
EBITDA Margin 22.10
Particulars MAR 2020 (Values in Cr)
Book Value / Share 944.61
ROE % 13.68
ROCE % 10.95
Total Debt to Total Equity 0.20
EBITDA Margin 17.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1459.23
ROE % 19.42
ROCE % 25.40
Total Debt to Total Equity 0.02
EBITDA Margin 34.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1236.56
ROE % 13.46
ROCE % 18.82
Total Debt to Total Equity 0.06
EBITDA Margin 28.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1111.56
ROE % 9.19
ROCE % 11.63
Total Debt to Total Equity 0.10
EBITDA Margin 21.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1032.48
ROE % 11.50
ROCE % 15.04
Total Debt to Total Equity 0.08
EBITDA Margin 25.97
Particulars MAR 2020 (Values in Cr)
Book Value / Share 920.13
ROE % 21.08
ROCE % 18.48
Total Debt to Total Equity 0.09
EBITDA Margin 30.49
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1727.70
Total Assets 38863.80
Total Liabilities 38863.80
Total Equity 28254.80
Share Outstanding 166818266
Price to Book Ratio 4.22
Return on Assets (%) 14.35
Return on Capital (%) 18.65
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1730.20
Total Assets 32285.10
Total Liabilities 32285.10
Total Equity 23286.10
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 13.96
Return on Capital (%) 18.47
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2419.20
Total Assets 29746.90
Total Liabilities 29746.90
Total Equity 19212.40
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 7.33
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2078.80
Total Assets 26616.80
Total Liabilities 26616.80
Total Equity 17641.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 7.33
Return on Capital (%) 9.6
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 205.30
Total Assets 23225.30
Total Liabilities 23225.30
Total Equity 15598.80
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 8.72
Return on Capital (%) 11.66
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1216.90
Total Assets 30359.30
Total Liabilities 30359.30
Total Equity 24240.80
Share Outstanding 166818466
Price to Book Ratio 4.22
Return on Assets (%) 14.30
Return on Capital (%) 17.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 645.80
Total Assets 25374.80
Total Liabilities 25374.80
Total Equity 20474.20
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 10.29
Return on Capital (%) 12.76
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2030.50
Total Assets 24495.60
Total Liabilities 24495.60
Total Equity 18336.20
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 6.62
Return on Capital (%) 7.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1646.50
Total Assets 21629.60
Total Liabilities 21629.60
Total Equity 16983.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 10.10
Return on Capital (%) 12.04
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 39.20
Total Assets 19475.80
Total Liabilities 19475.80
Total Equity 15191.90
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 15.08
Return on Capital (%) 18.07
Particulars MAR 2024 (Values in Cr)
Net Income 7201.00
Cash from Operations 6548.00
Cash from Investing -4028.30
Cash from Financing -376.30
Net change in Cash 138.70
Free Cash Flow 8188.30
Particulars MAR 2023 (Values in Cr)
Net Income 6048.50
Cash from Operations 6958.90
Cash from Investing -4137.30
Cash from Financing -2686.10
Net change in Cash -935.90
Free Cash Flow 8091.20
Particulars MAR 2022 (Values in Cr)
Net Income 3061.40
Cash from Operations 3554.50
Cash from Investing -2638.70
Cash from Financing -242.20
Net change in Cash -70.10
Free Cash Flow 5020.50
Particulars MAR 2021 (Values in Cr)
Net Income 2883.50
Cash from Operations 4141.90
Cash from Investing -2266.00
Cash from Financing -29.80
Net change in Cash 1274.50
Free Cash Flow 5116.00
Particulars MAR 2020 (Values in Cr)
Net Income 1885.70
Cash from Operations 3694.60
Cash from Investing -492.30
Cash from Financing -2515.90
Net change in Cash -24.10
Free Cash Flow 4179.20
Particulars MAR 2024 (Values in Cr)
Net Income 5791.30
Cash from Operations 4769.20
Cash from Investing -3430.30
Cash from Financing 68.10
Net change in Cash 87.50
Free Cash Flow 6130.29
Particulars MAR 2023 (Values in Cr)
Net Income 3866.00
Cash from Operations 5835.60
Cash from Investing -3447.60
Cash from Financing -2696.90
Net change in Cash -1091.60
Free Cash Flow 6835.80
Particulars MAR 2022 (Values in Cr)
Net Income 2223.80
Cash from Operations 1827.50
Cash from Investing -2038.00
Cash from Financing 505.50
Net change in Cash -193.80
Free Cash Flow 3138.80
Particulars MAR 2021 (Values in Cr)
Net Income 3056.20
Cash from Operations 3962.20
Cash from Investing -1458.00
Cash from Financing -794.30
Net change in Cash 1261.90
Free Cash Flow 4819.70
Particulars MAR 2020 (Values in Cr)
Net Income 2775.80
Cash from Operations 2316.10
Cash from Investing -1689.20
Cash from Financing -224.10
Net change in Cash -74.10
Free Cash Flow 2742.29
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.16 37.45 3.55 499.34 37.54 / 77.70
BLISS GVS PHARMA LTD 151.80 19.00 1.58 1598.94 92.25 / 172.40
CIPLA LTD 1454.20 25.44 4.14 117443.01 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 410.00 142.36 4.15 1206.67 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.16 56.66 11.07 499.34 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.55 45.59 7.27 2167.00 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6595.05 128.08 24.26 16487.63 4050.15 / 8139.85
BLISS GVS PHARMA LTD 151.80 19.79 1.56 1598.94 92.25 / 172.40

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1239.90
  • 26 Days 1235.30
  • 10 Days 1231.50
  • 50 Days 1266.40
  • 12 Days 1230.10
  • 100 Days 1294.90
  • 20 Days 1235.70
  • 200 Days 1275.60
1236.22
PIVOT
First Resistance 1245.73
Second Resistance 1252.92
Third Resistance 1262.43
First Support 1229.03
Second Support 1219.52
Third Support 1212.33
RSI 48.38
MACD -5.18
Commodity Channel Index (CCI) 47.21
ADX 23.25
Williams % R -31.70

Over 1 Month

down

-3.83

Over 3 Months

down

-6.34

Over 6 Months

down

2.54

Over 1 Year

down

13.14

Over 3 Years

down

10.42

Over 5 Years

down

16.48

DR. REDDY S LABORATORIES Future

Future: Price

26 Dec
1246.15
30 Jan
1254.80
27 Feb
1255.20
25 May
0 100 200 300 400 500 600

Discount/Premium

26 Dec
0.75
30 Jan
9.40
27 Feb
9.80
25 May
0 1 2 3 4 5 6 7

Active Calls

1250.0
2375
1240.0
1952
1260.0
1671
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1220.0
1629
1200.0
1532
1230.0
909
25 Jul
0 500 1000 1500 2000 2500

DR. REDDY S LABORATORIES Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
10.13
Promoter Holdings
26.64
FII
41.74
DII
21.47
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
J P Morgan Chase Bank Na Public Shareholding 2.3723295E7 14.22
G V Prasad Shareholding of Promoter and Promoter Group 1.9219184E7 11.52
Satish Reddy Kallam Shareholding of Promoter and Promoter Group 1.6027126E7 9.6
Life Insurance Corporation Of India P & Gs Fund Public Shareholding 9348601.0 5.6
Kallam Satish Reddy Huf Shareholding of Promoter and Promoter Group 5523677.0 3.31
Nps Trust-a/c Sbi Pension Fund Scheme Tax Saver-tier 2 Public Shareholding 4432352.0 2.66
First Sentier Investors Icvc - Stewart Investors Asia Pacific Leaders Sustainability Fund Public Shareholding 3869125.0 2.32
Icici Prudential Value Discovery Fund Public Shareholding 3485572.0 2.09
Gunupati Venkateswara Prasad Huf Shareholding of Promoter and Promoter Group 2543418.0 1.52
Sbi Nifty Index Fund Public Shareholding 2489505.0 1.49
Hdfc Trustee Company Ltd. A/c Hdfc Nifty 50 Etf Public Shareholding 2241051.0 1.34
Nippon Life India Trustee Ltd-a/c-nippon India Nifty 50 Value 20 Index Fund Public Shareholding 2215922.0 1.33
Samrajyam Reddy Kallam Shareholding of Promoter and Promoter Group 1120499.0 0.67
Anuradha Gunupati Shareholding of Promoter and Promoter Group 9205.0 0.01
Sharathchandra Reddy Gunupati Shareholding of Promoter and Promoter Group 2600.0 0.0
Aps Trust Shareholding of Promoter and Promoter Group 0.0 0.0
Vsd Holdings & Advisory Llp Shareholding of Promoter and Promoter Group 0.0 0.0
K Vishal Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
K Shravya Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
Gunupati Mallika Reddy Shareholding of Promoter and Promoter Group 5139.0 0.0
G Vani Sanjana Reddy Shareholding of Promoter and Promoter Group 5140.0 0.0
Deepti Reddy Kallam Shareholding of Promoter and Promoter Group 5140.0 0.0

DR. REDDY S LABORATORIES

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-07-11 40.0 Final 2023-07-12 Equity shares 2022-07-11 30.0 Final 2022-07-13 Equity shares 2021-07-09 25.0 Final 2021-07-13 Equity shares 2020-07-13 25.0 Final 2020-07-15 Equity shares 2019-07-15 20.0 Final 2019-07-17 Equity shares 2018-07-16 20.0 Final 2018-07-18 Equity shares 2017-07-17 20.0 Final 2017-07-19 Equity shares 2016-07-18 20.0 Final 2016-07-20 Equity shares 2015-07-10 20.0 Final 2015-07-14 Equity shares 2014-07-11 18.0 Final 2014-07-15 Equity shares 2013-07-12 15.0 Final 2013-07-16 Equity shares 2012-06-28 13.75 Final 2012-07-03 Equity shares 2011-06-30 11.25 Final 2011-07-05 Equity shares 2010-07-02 11.25 Final 2010-07-06 Equity shares 2009-07-03 6.25 Final 2009-07-07 Equity shares 2008-07-04 3.75 Final 2008-07-08 Equity shares 2007-07-06 3.75 Final 2007-07-10 Equity shares 2006-07-07 0.0 Final 2006-07-11 Equity shares 2005-07-07 0.0 Final 2005-07-11 Equity shares
Ex-Date Ex-Bonus Ratio
2006-08-29 2006-08-28 1:1 1994-05-03 1994-04-08 2:1
Ex-Date Old FV NEW FV Record Date
2001-10-10 10.0 5.0 2001-10-25

Dr Reddy's Laboratories Limited Overview

Dr. Reddy's Laboratories Ltd, an eminent pharmaceutical company based in India, offers an extensive portfolio across Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Dominating its revenue, the Global Generics Segment, constituting about 83% in FY22, includes over 400 generic drugs with significant contributions from nervous system, gastrointestinal, and anti-infective drugs. The Pharmaceutical Services & Active Ingredients (PSAI) segment, accounting for 14% of revenues, underscores its position as one of the world's largest API manufacturers, benefiting its generics business with cost competitiveness. Meanwhile, its proprietary products focus on differentiated formulations, with subsidiary Aurgene Discovery advancing novel therapeutics for cancer and inflammation. Geographically, the USA leads its revenue share at 37%, followed by India and Russia. The company boasts 23 manufacturing facilities worldwide and maintains a strategic focus on niche products, injectables, and biosimilars to enhance profitability. FY21 saw partnerships for COVID-19 treatments, including the launch of the Sputnik-V vaccine in India. Recent divestments and acquisitions, such as the portfolio from Eton Pharmaceuticals, reflect its commitment to streamlining operations and expanding its product offerings, supporting its mission to provide affordable medications globally.

Dr Reddy Share Result Highlights

Metric

Value

Share Price (NSE)

₹1272.05 (as of 12 Nov 2024)

Market Cap

₹21,220.12 Cr (Q3 2024)

Day Range

₹1269.20 - ₹1288.40 (12 Nov 2024)

52-Week Range

₹1074.00 - ₹1421.49 (2023-2024)

Volume (Shares)

2,86,546 (12 Nov 2024)

PE Ratio (TTM)

22.35 (Q3 2024)

Earnings Per Share (EPS)

₹113.00 (Q3 2024)

Dividend Yield

0.62% (Q3 2024)

Net Profit Margin

28.18% (Q3 2024)

Effective Tax Rate

28.72% (Q3 2024)

Key Highlights

  • Dr Reddy share price currently stands at ₹1272.05 as of 12 Nov 2024, reflecting recent trading data.

  • Market Cap for Dr Reddy's reached ₹21,220.12 Cr in Q3 2024, emphasising its market strength.

  • Trading Volume shows high activity with 2,86,546 shares traded on 12 Nov 2024.

  • EPS for Dr Reddy's is ₹113.00 in Q3 2024, indicating solid earnings.

  • Dividend Yield for Dr Reddy shares recorded at 0.62% in Q3 2024, offering attractive shareholder returns.

Dr Reddy Share Annual Reports

Metric

Value

Annual Revenue

₹6678.80 Cr (Sep 2024)

Net Profit

₹1882.10 Cr (Sep 2024)

Operating Expense

₹4263.09 Cr (Sep 2024)

EBITDA

₹2929.20 Cr (Sep 2024)

Net Profit Margin

28.18% (Sep 2024)

Return on Equity (ROE)

19.42% (Q3 2024)

Book Value per Share

₹322.48 (Q3 2024)

Key Highlights

  • Dr Reddy share price is influenced by strong annual revenue, reaching ₹6678.80 Cr as of Sep 2024.

  • Net Profit stands at ₹1882.10 Cr (Sep 2024), underscoring profitability.

  • Operating Expense recorded at ₹4263.09 Cr for Sep 2024, highlighting operational control.

  • EBITDA of ₹2929.20 Cr (Sep 2024) reflects robust earnings before tax.

  • Indicators from this performance may impact Dr Reddy future share price, as market outlook is often shaped by financial stability.

Dr Reddy Share Dividend

Dividend Type

Dividend Amount

Ex-Date

Record Date

Final

₹40 per share

11 Jul 2023

12 Jul 2023

Final

₹30 per share

11 Jul 2022

13 Jul 2022

Final

₹25 per share

09 Jul 2021

13 Jul 2021

Final

₹25 per share

13 Jul 2020

15 Jul 2020

Final

₹20 per share

15 Jul 2019

17 Jul 2019

Final

₹20 per share

16 Jul 2018

18 Jul 2018

Key Highlights

  • Dr Reddy share price reflects consistent returns with regular dividends, enhancing investor confidence.

  • The most recent dividend was ₹40 per share with an ex-date of 11 Jul 2023.

  • Dr Reddy's long-term dividend history showcases its commitment to rewarding shareholders.

About DR. REDDY S LABORATORIES

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by DR. REDDY S LABORATORIES

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Dr Reddys Laboratories Ltd?

Answer Field

The share price of Dr Reddys Laboratories Ltd for NSE is ₹ 1245.4 and for BSE is ₹ 1242.75.

What is the Market Cap of Dr Reddys Laboratories Ltd?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE is ₹ 2,07,75.55 Cr. and for BSE is ₹ 2,07,31.34 Cr. as of now.

What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?

Answer Field

The 52 Week High and Low of Dr Reddys Laboratories Ltd for NSE is ₹ 1421.49 and ₹ 1094.24 and for BSE is ₹ 1420.20 and ₹ 1094.88.

How to Buy Dr Reddys Laboratories Ltd share?

Answer Field

You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Dr Reddys Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 13.14%.

What is the Current Share Price of Dr Reddys Laboratories Ltd?

Answer Field

Dr Reddys Laboratories Ltd share price is for NSE ₹ 1245.4 & for BSE ₹ 1242.75 as on Dec 12 2024 03:30 PM.

What is the Market Cap of Dr Reddys Laboratories Ltd Share?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE ₹ 2,07,75.55 & for BSE ₹ 2,07,31.34 as on Dec 12 2024 03:30 PM.

What is the P/E Ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Dec 12 2024 03:30 PM the price-to-earnings (PE) ratio for Dr Reddys Laboratories Ltd share is 21.62.

What is the PB ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Dec 12 2024 03:30 PM, the price-to-book (PB) ratio for Dr Reddys Laboratories Ltd share is 322.47.

How to Buy Dr Reddys Laboratories Ltd Share?

Answer Field

You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Dr Reddys Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Dr Reddys Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Dr Reddys Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Popular FAQs

Who is the CEO of Dr Reddy's Laboratories Ltd?

Erez Israeli has held the position of CEO at Dr Reddy's Laboratories Ltd since 1 Aug 2019. He leads the company in advancing pharmaceutical innovations and global market reach, focusing on sustainable growth and maintaining Dr Reddy's competitive position within the industry.

 

When was Dr Reddy's Laboratories Ltd established?

Dr Reddy's Laboratories Ltd was founded in 1984 in Hyderabad, India, by Dr. Anji Reddy. The company began by manufacturing Active Pharmaceutical Ingredients (APIs) and quickly expanded to become one of India’s leading pharmaceutical companies with a significant global presence.

 

What factors influence the Dr Reddy Share Price?

Dr Reddy share price is influenced by multiple factors, including financial performance, revenue growth, and profitability. Sector trends, global market conditions, regulatory changes, and investor sentiment also impact share value, shaping the overall market perception of Dr Reddy's potential for future growth.

 

Is Dr Reddy's Laboratories Ltd debt free?

Dr Reddy's Laboratories Ltd is not entirely debt-free; however, the company maintains a balanced debt-to-equity ratio, ensuring debt levels remain manageable. This strategic financial management allows Dr Reddy's to invest in growth opportunities while maintaining financial stability and supporting long-term shareholder value.

 

What is the CAGR of Dr Reddy Share?

The Compound Annual Growth Rate (CAGR) for Dr Reddy share is 6% over 10 years, 19% over 5 years, 10% over 3 years, and 19% over the last year. These figures reflect the company’s growth trajectory and its consistent performance in the pharmaceutical sector.

 

How has the Dr Reddy Share Price performed over the past year?

Over the past year, Dr Reddy share price has demonstrated a positive performance, showing a 19% growth in CAGR. This growth highlights investor confidence and reflects the company’s strong market position, profitability, and financial resilience within the highly competitive pharmaceutical industry.

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader